Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.
Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.
The Lung Cancer Prognostic Index (LCPI) provides additional relevant prognostic data for patients with NSCL and may lead to better outcomes.
Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for CliniciansJuly 24, 2017
A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.
Two recent studies examined the benefits of using a 3D bioabsorbable marker to indicate the tumor bed in women with breast cancer who underwent breast conserving surgery (BCS).
An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.
Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older PatientsJune 27, 2017
Results from a sub-analysis of the impact of age on the safety and efficacy of lenvatinib in patients with RR-DTC in the SELECT trial showed that lenvatinib significantly increased PFS.
Regular use of NSAIDs after diagnosis of colorectal cancer correlated with improved survival in survivors with KRAS wild-type tumors.
Research on the effects of research demonstrated that oncology-related clinical trials provide measurable benefits in terms
Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.
Axalimogene filolisbac, an intravenous vaccine currently in clinical trials, could prevent often-fatal cervical cancer relapse.
Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.
A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.
Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer RiskApril 19, 2017
Whole genome sequencing of more than 3000 survivors of childhood cancers demonstrates the value of genetic testing for potential second cancers in this population.
Continuing immunotherapy after disease progression extends survival for some patients with head and neck cancer.
The joint report states that overall cancer rates have decreased for men, women, and children in all major race and ethnic groups. However, progress has been limited for some cancers.
Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.
A phase 3 analysis of SWOG Intergroup Trial S0033 reveals that imatinib significantly extends survival in patients with GIST.
Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.
The addition of pravastatin to first-line chemotherapy did not improve overall survival or progression-free survival in patients with small-cell lung cancer.
Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Investigators determined the impact of socioeconomic status on disease status at presentation and survival among patients with head and neck squamous cell carcinoma.
Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.
There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.
The timing of surgery taking place following an endometrial cancer diagnosis may adversely impact survival.
Seluminitinib in combination with an AKT inhibitor did not improve survival compared with modified FOLFOX in previously treated metastatic pancreatic cancer.
Weak social ties are associated with poorer survival and a higher risk of breast cancer recurrence, researchers say.
A new meta-analysis examines the impact of palliative care services on patients' and caregivers' quality of life and outcomes.
CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast CancerOctober 12, 2016
Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|